

Table S1. Therapeutic interventions in the study population

	All (<i>n</i> = 74)	ILD group (<i>n</i> = 32)	Non-ILD group (<i>n</i> = 42)	<i>p</i> value
Days from onset to PCP therapy	8.8 (6.0-12.7)	8.0 (4.5-11.5)	10.3 (6.3-13.3)	0.338
PCP therapy				
TMP-SMX	64 (86.5)	27 (84.4)	37 (88.1)	0.737
Pentamidine	9 (12.2)	5 (15.6)	4 (9.5)	0.488
Atovacon	1 (1.4)	0 (0.0)	1 (2.4)	1.000
Dose of TMP (mg/kg/day)	8.9 (5.9–14.6)	7.1 (5.4–12.8)	11.6 (6.3– 15.2)	0.138
Adjunctive steroid	73 (98.6)	32 (100)	41 (97.6)	1.000
Corticosteroid pulse therapy	19 (25.7)	15 (46.9)	4 (9.5%)	<0.001
CMV therapy	22 (29.7)	8 (25.0)	14 (33.3)	0.608
Mechanical ventilation	21 (28.4)	10 (31.3)	11 (26.2)	0.795

Data presented as counts (%) or medians (IQR, 25%–75%). The *p* values refer to

comparisons between the ILD and non-ILD groups.

ILD, interstitial lung disease; **PCP, pneumocystis pneumonia**; TMP-SMX,

trimethoprim/sulfamethoxazole; CMV, cytomegalovirus.